Celebrate the holidays in style, just like Lady Gaga, with these festive Cider Floral Decor Tights-and they're just $5.

For travelers without TSA PreCheck, wearing shoes that easily slide on and off makes navigating airport security checkpoints a tad more efficient. Let’s face it, we’ve all been the passenger with mere ...

Despite the ongoing controversy surrounding her most recent song "+57," Karol G was all smiles as she arrived at the 2024 ...

Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant improvement ...

Credit: Doidam 10 via Shutterstock. Teva Pharmaceuticals’ TEV-‘749 (olanzapine) has shown statistical improvement in schizophrenia symptoms in a Phase III trial. The Phase III SOLARIS trial ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA1.92%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive ...

Oct. 31 (UPI) --The European Commission fined Teva Pharmaceuticals $503 million for delaying competition posed by rival generic drugmakers, the company's second major financial penalty this month.

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. The European ...

BRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its ...

It is not Teva's first EU fine. EU regulators in 2020 fined the company and drug-maker Cephalon -- which Teva later bought -- for colluding to delay a cheaper generic version of a sleep disorder drug.

Teva “spread information contradicted by health authorities’ findings, seeking to sow doubt on the safety, efficacy and therapeutic equivalence of the rival product,” the EU Commission said.